Efficacy of gabapentin versus trospium chloride for prevention of catheter-related bladder discomfort inside the surgical intensive care unit: A prospective, randomised, controlled clinical study
DOI:
https://doi.org/10.62838/jccm-2026-0018Keywords:
catheter-related bladder discomfort, CRBD four-point severity scale, gabapentin, surgical intensive care unit, trospium chlorideAbstract
Introduction: Catheter-related bladder discomfort (CRBD) after perioperative catheterisation of the urinary bladder
(COUB) is not uncommon.
Aim of the study: We evaluated the efficacy of both oral gabapentin and trospium in preventing CRBD during the early postoperative period in patients admitted to the surgical intensive care unit (S-ICU).
Material and Methods: 120 patients aged 20–65 years, ASA I, II or III who were admitted to S-ICU after undergoing elective spinal surgery (ESS) with COUB were included. They were randomly assigned to be administered either an oral 400 mg gabapentin capsule (Group G) or an oral 60 mg slow-release trospium chloride capsule (Group T) or nothing (Group C). The primary goal was the occurrence of CRBD and its severity at 1, 2, 6, 12, and 24 hours after the study drug administration (SDA).
Results: Group G and group T had a statistically significant lower incidence of CRBD than group C at 1, 2, 6, 12, and 24 hours after SDA, respectively. Both had considerably lower severity than group C in the first two hours only (P= 0.001 and 0.001, respectively). Group T had non-significantly lower incidence and severity of CRBD than group G. Group G had significantly lower mean total fentanyl requirements for up to 24 hours after SDA than group T and group C (P < 0.001).
Conclusion: Both oral gabapentin capsules and slow release trospium chloride capsules administered postoperatively, significantly decreased both the incidence of CRBD and its severity in the early postoperative period amongst S-ICU patients, without significant differences between the two drugs.
Downloads
References
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ahmed Moustafa Mohamed, Wessam Zaher Selima (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.
This journal provides immediate open access to its content under the Creative Commons BY 4.0 license. Authors who publish with this journal retain all copyrights and agree to the terms of CC BY 4.0 license. The journal allows free unlimited access to all its contents without any restrictions upon publication to all users. The published materials are free to be shared and adapted, giving appropriate credit and indicating if changes were made.






